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Summary. Background: Inherited platelet function disor-
ders (PFDs) are heterogeneous, and identification of the
underlying genetic defects is difficult when based solely
on phenotypic and clinical features of the patient. Objec-
tive: To analyze 329 genes regulating platelet function,
number, and size in order to identify candidate gene
defects in patients with PFDs. Patients/methods: Targeted
analysis of candidate PFD genes was undertaken after
next-generation sequencing of exomic DNA from 18
unrelated index cases with PFDs who were recruited into
the UK Genotyping and Phenotyping of Platelets (GAPP)
study and diagnosed with platelet abnormalities affecting
either Gi signaling (n = 12) or secretion (n = 6). The
potential pathogenicity of candidate gene defects was
assessed using computational predictive algorithms.
Results: Analysis of the 329 candidate PFD genes identi-
fied 63 candidate defects, affecting 40 genes, among index
cases with Gi signaling abnormalities, while 53 defects,
within 49 genes, were identified among patients with
secretion abnormalities. Homozygous gene defects were
more commonly associated with secretion abnormalities.
Functional annotation analysis identified distinct gene
clusters in the two patient subgroups. Thirteen genes with
significant annotation enrichment for ‘intracellular signal-
ing’ harbored 16 of the candidate gene defects identified
in nine index cases with Gi signaling abnormalities. Four
gene clusters, representing 14 genes, with significantly
associated gene ontology annotations were identified
among the cases with secretion abnormalities, the most
significant association being with ‘establishment of pro-
tein localization.’ Conclusion: Our findings demonstrate
the genetic complexity of PFDs and highlight plausible
candidate genes for targeted analysis in patients with
platelet secretion and Gi signaling abnormalities.
Keywords: bioinformatics; bleeding; blood platelet
disorders; high-throughput DNA sequencing; platelets.
Introduction
Inherited platelet function disorders (PFDs), associated
with normal or reduced platelet counts, are characterized
by lifelong episodes of excessive mucocutaneous bleeding
and account for a significant proportion of bleeding
diatheses [1]. Identification of the underlying genetic
defects in these disorders is complicated by the differences
in clinical expression of the bleeding symptoms in affected
individuals, and the redundancy in platelet receptor and
signaling pathways, which mean that defects in the differ-
ent pathways are not easily discriminated at a phenotypic
level.
First described in 1962, light transmission aggregome-
try (LTA) remains the gold standard method for diagnos-
ing PFDs, while assessment of platelet-dense granule ATP
release provides an additional valuable tool for diagnos-
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ing platelet secretion disorders [2]. Thus, we have shown
that many PFDs can be diagnosed using a combination
of LTA and ATP secretion analysis and a streamlined
panel of six platelet agonists at specified concentrations
[3]. Furthermore, most PFDs can be assigned to one of
three major diagnostic groups having defects in the
thromboxane A2 pathway, Gi receptor signaling, and
dense granule secretion, with the latter two groups
accounting for almost two-thirds of those participants
who had a defect in platelet aggregation or ATP secretion
[3].
LTA and platelet ATP secretion profiling will identify
candidate genes for targeted gene analysis in a small num-
ber of PFDs. Previous examples of this phenotype-driven
approach have led to the identification of a homozygous
P2RY12 defect in a patient whose platelets displayed a
profile that was consistent with a P2Y12 ADP receptor
defect and of heterozygous TBXA2R defects disrupting
function and trafficking of the thromboxane A2 receptor
in two patients whose platelets demonstrated defects in
arachidonic acid metabolism and reduced responses to
the thromboxane analogue U46619 [4,5]. However, in
most cases, identification of the causative gene based
solely on the clinical and laboratory phenotype is rarely
achieved in PFDs due to the heterogeneity and complex-
ity of these disorders.
Next-generation sequencing (NGS) technologies that
permit the simultaneous analysis of large numbers of
genes have facilitated the identification of gene defects in
patients with PFDs, where the underlying genetic defect
was previously unknown [6–13]. Through the UK Geno-
typing and Phenotyping of Platelets (UK-GAPP) study
[14], we are combining the power of NGS with targeted
analysis of genes that have previously been associated
with PFDs in humans or are known or predicted to
encode proteins that mediate platelet function, formation,
and morphology. This approach has allowed us to iden-
tify a novel HPS4 defect in a patient with Hermansky–
Pudlak syndrome [9] and more recently revealed a high
incidence of alterations affecting FLI1 and RUNX1 in
patients presenting with mild bleeding symptoms charac-
terized by defects in platelet-dense granule secretion [13].
We now describe the results of a targeted analysis of
329 platelet genes, which are known or predicted to have
a role in regulating platelet function, size, and number, in
18 unrelated index patients diagnosed with PFDs and
recruited to the UK-GAPP study and shown to have
defects in either Gi receptor signaling or dense granule
secretion.
Subjects and methods
Subjects and platelet phenotyping
Index cases from 18 families, recruited through UK Com-
prehensive Care Haemophilia Centres and enrolled in the
UK-GAPP study between August 2006 and August 2012,
were investigated (ISRCTN 77951167). Where available,
affected relatives were also investigated. All participants
had abnormal bleeding symptoms compatible with a
PFD (spontaneous mucocutaneous bleeding or abnormal
bleeding following trauma or invasive procedures) and
satisfied the criteria for inclusion in the study described
earlier, including having coagulation factor levels within
the local laboratory reference ranges and no clinical evi-
dence of acquired platelet dysfunction [3]. Platelet func-
tion testing at the referring centers had previously
excluded the possibility of Glanzmann’s thrombasthenia,
Bernard–Soulier syndrome, or Hermansky–Pudlak syn-
drome. The study was approved by the National
Research Ethics Service Committee West Midlands–
Edgbaston (REC reference: 06/MRE07/36), and partici-
pants gave written informed consent in accordance with
the Declaration of Helsinki. Blood from participants and
healthy volunteer subjects was sampled into 3.1% sodium
citrate in evacuated tubes (S-Monovette 0.106 mol L–L;
Sarstedt, Leicester, UK) and platelet-rich plasma was pre-
pared as described previously [3]. Platelet aggregation in
response to a panel of agonists at different concentrations
and ATP secretion were assessed using a dual-channel
Chronolog lumiaggregometer (Model 460 VS; Chronolog,
Havertown, PA, USA), as previously described [3]. Plate-
let phenotyping was undertaken for each participant in
parallel with a healthy volunteer, and results were com-
pared with the control reference ranges for platelet aggre-
gation and secretion previously established by our group
[3,4].
Genetic analysis
Genomic DNA was isolated from peripheral blood using
the Puregene DNA extraction kit (Qiagen, Manchester,
UK) and, after enrichment of coding regions and intron/
exon boundaries (10 bp flanking the exons) using the Agi-
lent SureSelect All Exon 50 Mb kit (Agilent Technologies,
Wokingham, UK), DNA sequencing was undertaken on
the HiSeq 2000 from Illumina (Little Chesterford, UK).
Sequence reads were aligned to the reference genome
(hg19) using Novoalign (Novocraft Technologies, Sdn
Bhd, Malaysia). Duplicate reads and reads that mapped
to multiple locations in the exome were excluded from
further analysis. Depth of sequence coverage was calcu-
lated using custom scripts and the BedTools package [15],
and those with a sequence coverage below four were
excluded. Single nucleotide variations (SNVs) and small
insertions/deletions (indels) were identified and filtered for
quality using the SAM tools [16] package and in-house
software tools. Variants were annotated with respect to
genes and transcripts using the ANNOVAR tool [17].
Further analysis was targeted at variants within a panel
of 329 candidate PFD genes, which represents an exten-
sion of a previously published list of candidate genes [9]
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(Data S1). The original list consisted of 216 genes previ-
ously associated with PFDs in humans, orthologs of
genes linked to platelet dysfunction in selected animal
models, and genes that encoded recognized mediators of
platelet activation that had not been previously associated
with PFDs [9]. For this study, the panel was extended to
include genes that have been more recently identified as
encoding proteins with a role in platelet function, as well
as genes encoding proteins involved in the regulation of
platelet formation and morphology. Variants within these
genes were filtered for novelty by comparison to
dbSNP129 and dbSNP132 (EVS; (http://evs.gs.washing-
ton.edu/EVS/), the 1000 Genomes Project, and an ‘in-
house’ database of 600 exomes, and those with a minor
allele frequency (MAF) > 0.01, as determined by the 1000
Genome Project or EVS, were excluded (Data S2). Nov-
elty was confirmed by comparison to dbSNP138.
Identification of candidate gene defects
Candidate gene defects were identified using a combina-
tion of bioinformatic tools and, where possible, by tar-
geting those variants that were shared by index cases
with their affected family members. The potential effects
of nonsynonymous amino acid substitutions and indels
on protein function were predicted using Sorting Intol-
erant From Tolerant (SIFT; http://sift.bii.a-star.edu.sg/),
Polymorphism Phenotyping v2 (PolyPhen-2; http://genet-
ics.bwh.harvard.edu/pph2/), and MutationTaster (http://
www.mutationtaster.org/). The potential effects on splic-
ing of those variants predicted to be benign by the
three latter tools, and all remaining synonymous and
intronic variants, were then predicted using Human
Splice Finder (HSF; http://www.umd.be/HSF/), Splice-
Port (http://spliceport.cbcb.umd.edu/), and Alternative
Splice Site Predictor (ASSP; http://wangcomputing.com/
assp/index.html). Those variants that were predicted to
be detrimental by at least one of these bioinformatic
tools were considered to be candidate gene defects
(Data S2).
Functional annotation analysis
The Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) (http://david.abcc.ncifcrf.gov)
was used to perform functional annotation analysis on
those genes identified as having candidate defects. Using
the Ensembl gene ID for each gene, a functional annota-
tion chart was generated by selecting the GO-
TERM_BP_FAT annotation category in DAVID, which
allows enrichment analysis to highlight the most relevant
Gene Ontology (GO) terms associated with a given gene
list. The significance of gene enrichment in annotation
terms was measured using the Expression Analysis Sys-
tematic Explorer (EASE) score, which is a modified
Fisher Exact P-value, with application of the Benjamini
correction for multiple comparisons, as applied in
DAVID, with the threshold set at 0.05.
Results
Characteristics of the participants studied
A subgroup of 18 index cases (F1.1 to F18.1; 13 females
and five males), who ranged in age from 6 to 82 years,
and were recruited into the UK GAPP study [3,18] on
the basis of abnormal bleeding symptoms and a sus-
pected inherited platelet disorder, were investigated. All
index cases had been diagnosed as having PFDs on lu-
miaggregometry as described earlier [3]. Twelve of the
index cases (F1.1 to F12.1) were diagnosed as having Gi-
like abnormalities characterized by transient platelet
aggregation in response to 10 lmol –L ADP and the
absence of a secondary wave of aggregation in response
to 10 lmol –L epinephrine. The other six index cases
(F13.1 to F18.1) were classified as having dense granule
secretion defects, which were characterized by a reduc-
tion in ATP secreted in response to protease-activated
receptor–1 specific peptide (SFLLRN; 100 lmol L–L ) to
a level below the 5th percentile for the response in
healthy volunteers [3]. In addition to the index cases, we
studied four individuals who were first-degree affected
relatives of each of the index cases (F1.1 to F4.1). These
individuals, denoted F1.2 to F4.2, also had Gi signaling
abnormalities.
Exome sequencing and target gene analysis
Exome sequencing and targeted analysis of selected
platelet genes were undertaken for all participants (18
index cases, F1.1 to F18.1, and four affected relatives,
F1.2 to F4.2). After calculation of the depth of
sequence coverage, variants with a coverage of less than
four were removed from any further analysis. The aver-
age read depth for the remaining variants across all
samples was 106.4. Alignment of exome sequence data
to the human genome identified ~25 000 variants in the
exome of each participant (Data S3). Restriction of the
analysis to 329 candidate PFD genes, based largely on
a previously described list [9], reduced the number of
variants to < 350 per participant. Filtering of the data
for novelty, and removal of those variants having
MAFs > 0.01, reduced the number to < 30 per partici-
pant. After removal of those variants that were pre-
dicted to be benign using all bioinformatic tools
described in Methods, a median of 4.5 (range 2–9) can-
didate gene defects were identified in those participants
with Gi signaling abnormalities and 7.5 (range 3–11) in
those participants with secretion defects (Data S3). For
those four index cases where an affected family member
was also investigated, the number of potentially deleteri-
ous candidate gene defects was reduced by ~50% after
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filtering for those variants that were shared between
affected individuals.
Identification of candidate gene defects in patients with Gi
signaling abnormalities
A total of 63 candidate gene defects, within 40 genes,
were identified among the 12 index cases with Gi signaling
abnormalities, of which 70% (44/63) were missense altera-
tions and 17 were previously unreported (Table 1). In
addition to the candidate missense alterations, eight in-
dels, one of which was predicted to cause a frame shift,
and 11 potential splicing defects were identified. All can-
didate variations identified in this cohort were inherited
as heterozygous defects (Table 1).
To prioritize the candidate gene defects, functional
annotation analysis was undertaken using the DAVID
tool [19], which, for a given list of genes, clusters gene
products in terms of their associated biological processes,
cellular components, and molecular functions, by identify-
ing those significantly associated GO annotations. Func-
tional annotation analysis of the 40 genes that were
identified as having the 63 candidate gene defects among
the index cases with Gi signaling abnormalities, revealed
a single cluster, comprising 13 genes, which showed sig-
nificant annotation enrichment for ‘intracellular signaling’
(P = 0.0038). This cluster harbored 16 of the candidate
gene defects that were identified in nine of the 12 index
cases with Gi signaling abnormalities (Tables 2 and 3).
Identification of candidate gene defects in patients with
dense granule secretion abnormalities
Fifty-three candidate defects, within 49 genes, were identi-
fied among the patients with dense granule secretion
defects, approximately half (25/53) of which had not been
reported previously. Missense alterations accounted for
68% (36/53) of the candidate defects identified. Eight indels
and nine potential splicing defects were also identified. Five
of the indels were predicted to result in frame shifts
(Table 1). Interestingly, homozygous candidate gene
defects were more commonly associated with secretion
abnormalities. Thus, eight candidate gene defects (two mis-
sense, five indels, and one splicing defect), affecting eight
different genes, were inherited as homozygous alterations
in four of the patients with dense granule secretion defects
(Table 1). Three of these patients harbored more than one
homozygous defect, and each of the four patients had also
inherited between seven and 11 additional heterozygous
candidate defects in the panel of 329 genes.
Functional annotation analysis was carried out for the
49 genes that harbored the 53 candidate gene defects
identified among the index cases with secretion abnormal-
ities. This revealed four clusters of between 11 and 13
genes that had significantly associated GO annotations
(Tables 2 and 4). There was considerable overlap in the
genes present in each cluster, with a total of 14 genes
being represented by all four clusters, with the most sig-
nificant enrichment being for ‘establishment of protein
localization’ (P = 0.00032). Of the eight genes bearing
candidate homozygous defects, only one, HOOK3,
remained after prioritization of the candidate genes using
functional annotation analysis. There was no overlap
between the 13 genes that showed significant annotation
enrichment for ‘intracellular signaling’ among patients
with Gi signaling abnormalities and the 14 genes repre-
sented by four clusters identified by functional analysis in
the patients with dense granule secretion abnormalities.
Discussion
In this study, we have investigated the use of exome
sequencing and targeted gene analysis to identify candi-
date gene defects in PFDs by studying 12 index cases
diagnosed with Gi signaling abnormalities and six index
cases diagnosed with platelet secretion defects. Inherent in
our approach was our prediction that candidate defects
occur in genes encoding platelet proteins that function in
the same or related pathways among patients with similar
phenotypes. For example, a defect in Gi signaling may be
explained by one or more alterations in the genes encod-
ing the Gi-coupled platelet receptors and the proteins par-
ticipating in their downstream signaling pathways.
Likewise, a reduction in ATP secretion could be due to
one or more defects in genes regulating granule formula-
tion and/or exocytosis.
Table 1 Genotype and nature of candidate gene defects identified in two subgroups of index cases
Variant type
Gi signaling abnormality (n = 12) Secretion abnormality (n = 6)
Hetero Homo Total Novel Hetero Homo Total Novel
Missense 44 0 44 15 34 2 36 15
Indel/frame shift 1 0 1 0 2 3 5 5
Indel/inframe 7 0 7 2 1 2 3 3
Splicing 11 0 11 0 8 1 9 2
Total 63 0 63 17 45 8 53 25
Indel/frame shift, insertion or deletion predicted to cause a frame shift; indel/inframe, insertion or deletion that does not disrupt the reading
frame; hetero, heterozygous variant; homo, homozygous variant.
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Comparison of the exome sequence data with the
human genome sequence identified ~350 variants in the
panel of 329 candidate platelet function defect genes for
each index case. A combination of strategies was used to
exclude those variants that were unlikely to contribute to
the phenotype observed in the index cases and enrich the
data for potentially causative gene defects. The data were
first filtered by excluding common variants listed on pub-
lic and in-house databases and restricting the analysis to
unique or rare variants (MAF < 0.01), which were pre-
dicted to be deleterious using a selection of bioinformatic
tools. This identified a number of plausible candidate
gene defects with a median of 4.5 potentially deleterious
defects remaining in the index cases with Gi signaling
abnormalities and 7.5 in those with secretion defects fol-
lowing use of these strategies to filter the exome sequence
data, which could be reduced by ~50% by considering,
where possible, only those variants that were shared with
an affected relative. Because unaffected family members
were not recruited to the study, it was not possible to
achieve a further reduction in the number of plausible
candidate gene defects by excluding those candidate vari-
ants that were also present in DNA from unaffected rela-
tives. Nevertheless, these findings emphasize the
heterogeneous nature of inherited PFDs, and the likely
contribution of multiple genetic defects, which also inter-
act with acquired factors, to determine the overall expres-
sion of a bleeding tendency. Interestingly, homozygous
candidate gene defects were more common among those
index cases diagnosed with secretion abnormalities than
among those with Gi signaling defects (Fisher’s Exact test
P = 0.0014), suggesting that abnormalities in platelet
secretion may be more likely to be inherited as autosomal
recessive traits and to be due to severe or complete loss
of function, rather than haploinsufficiency, of specific
platelet proteins. Additionally, some of the heterozygous
candidate gene defects that have been identified occur in
genes that are usually associated with autosomal recessive
traits. For example, defects in LYST are associated with
the rare autosomal recessively inherited Chediak–Higashi
syndrome, while platelet P2Y12 receptor deficiency is usu-
ally due to recessive inheritance of P2RY12 defects. Our
findings suggest that heterozygous defects in these genes
could affect platelet function as dominant traits and con-
tribute to the expression of a mild bleeding tendency.
Indeed, it is plausible that a heterozygous defect in one of
these genes could, in combination with a heterozygous
defect in one or more related genes, such as genes encod-
ing proteins that function in the same signaling or traf-
ficking pathway, contribute to the overall bleeding risk.
In support of this, we have previously described two het-
erozygous P2RY12 defects in patients with type 1 von
Willebrand disease and shown that these are likely to
contribute to the bleeding tendency in the families with
the defects providing further evidence for locus heteroge-
neity in type 1 von Willebrand disease [20,21]. Similarly,







change Zygosity Effect dbSNP ID
1000 genomes
MAF EVS MAF
F3.1 P2RY12 c.365G>A p.R122H Heterozygous Missense Novel
F12.1 c.772C>A p.P258T Heterozygous Missense rs202099742 0.000077 No data
F7.1 PLCB3 c.130C>T p.R44C Heterozygous Missense Novel
F1.1 UNC13A c.1032_1034delGGA p.E344del Heterozygous Inframe deletion Novel
F8.1 c.739G>A p.E247K Heterozygous Missense rs200805380 0.00024 No data
F8.1 VAV2 c.1998C>G p.I666M Heterozygous Missense rs144269361 0.0009 No data
F9.1 RGS19 c.650C>T p.A217V Heterozygous Missense Novel
F2.1 TLR2 c.2186A>G p.N729S Heterozygous Missense rs61735278 0.001 0.0005
F3.1 PTGIR c.44T>C p.V15A Heterozygous Splice defect rs200213497 0.002035 No data
F5.1 PLA2G4C c.410C>T p.A137V Heterozygous Missense rs11564532 0.001615 0.0009
F11.1 c.454G>T p.V152F Heterozygous Missense rs11564534 0.009918 0.0046
F3.1 ARHGEF12 c.989A>G p.H330R Heterozygous Splice defect rs187048571 0.000835 0.0011
F1.1 PTPRC c.367G>C p.D123H Heterozygous Splice defect rs41269905 0.0085 0.01399
F8.1 ADCY6 c.358C>T p.R120C Heterozygous Missense rs55770045 0.01261 0.0109
F5.1 PDZD3 c.291G>A p.A97= Heterozygous Splice defect rs150917049 0.000385 No data
F7.1 PRKD1 c.1181G>A p.R394K Heterozygous Splice defect Novel
MAF, minor allele frequency; EVS, exome variant server.
Table 2 Functional annotation analysis of genes harboring candidate
defects in two subgroups of index cases
Annotation term P value* No. of genes
Gi signaling abnormality
Intracellular signaling 3.8 9 103 13
Secretion abnormality
Establishment of protein localization 3.2 9 104 13
Protein transport 5.9 9 104 13
Protein localization 4.1 9 104 13
Vesicle-mediated transport 8.3 9 104 11
*Terms are sorted based on the Benjamini-corrected Modified Fisher
Exact P-value as reported in DAVID (http://david.abcc.ncifcrf.gov).
P < 0.05 denotes significance.
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our findings in this study emphasize the heterogeneity
and likely polygenic inheritance of mild platelet bleeding
disorders.
Defects were identified in 40 of the 329 platelet genes
analyzed among the patients with the Gi signaling abnor-
malities and in 49 genes among the patients with the
dense granule secretion defects. Ten genes were identified
as bearing defects in both patient subgroups. Given the
different phenotypes, the defects in these 10 genes are
unlikely to explain the platelet abnormalities in the
patients. Furthermore, the overlap in gene sets between
the two patient subgroups indicates that further prioriti-
zation of the candidate gene defects would be desirable
before undertaking further studies to investigate their
potential contribution to the platelet abnormalities in the
patients. A handful of the candidate defects were present
in genes that had previously been associated with platelet
bleeding disorders, including P2RY12, VPS33B, GATA1,
ANKRD26, HPS1, VWF, and LYST [22]. However, the
majority of candidate defects were present in genes that
have not previously been associated with platelet bleeding
disorders in humans.
We also investigated the utility of functional annota-
tion analysis as a tool for prioritizing candidate gene
defects for follow-up studies of their potential role in
PFDs that are characterized by defects in Gi signaling
and secretion. This approach identified a single cluster of
13 genes that showed significant annotation enrichment
for intracellular signaling, and harbored defects in nine of
the 12 patients whose platelets displayed Gi signaling
abnormalities, characterized by reduced aggregation in
response to ADP and epinephrine. Interestingly, this clus-
ter includes P2RY12 encoding the P2Y12 ADP receptor,
which is an essential component of the Gi-linked receptor
pathway that is necessary for full platelet activation [23].
Two candidate defects predicting amino acid substitutions
in P2RY12 were identified in two patients. One of these,
predicting a p.P258T substitution in the third extracellular
loop of the receptor, was previously identified as a hetero-
zygous defect in a patient with abnormal bleeding, whose
platelets failed to aggregate in response to low concentra-
tions of ADP [24]. The second predicted a p.R122H sub-
stitution in the highly conserved DRY motif of P2Y12
which is thought to play a role in regulating conforma-
tional states of the receptor. This mutation has not been
described previously. However, our group has recently
described a patient with a homozygous mutation predict-
ing substitution of the same arginine residue by cysteine.
The recombinant R122C variant showed reduced cell sur-
face expression in platelets and agonist-independent inter-
nalization when expressed in cell lines [25]. Further work
will be required to determine whether the R122H variant
behaves similarly. Defects in ADCY6 and PTGIR, which
encode adenyl cyclase and the prostacyclin receptors,
respectively, are also included in this cluster. These could
potentially cause an increase in intracellular cAMP and
inhibition of platelet aggregation, opposing the effect of
Gi signaling and appearing as impaired Gi-type responses
on platelet function testing [26].
All 14 genes highlighted by functional annotation
analysis of the genes bearing defects among the index
cases with secretion abnormalities encode proteins
involved in protein localization or transport, and all six
index cases possessed a mutation in at least one of these
genes. Of particular note, six genes in this group encode
members of the syntaxin family of proteins, known for
their role in SNARE-complex activity [27], mediating ves-
icle formation, transport, and secretion from the cell.
Thus, 67% of the index cases diagnosed with a dense
granule secretion defect had alterations in one of the syn-







change Zygosity Effect dbSNP ID
1000 genomes
MAF EVS MAF
F14.1 VAV1 c.630T>C p.T210= Heterozygous Splicing defect Novel
F18.1 STX7 c.572A>G p.D191G Heterozygous Missense rs144864017 0.000231 No data
F18.1 STX2 c.94T>G p.F32V Heterozygous Missense rs137928907 0.018761 0.0089
F18.1 STXBP4 c.287+7A>G N/A Heterozygous Splicing defect rs181690254 0.003921 0.0023
F15.1 LYST c.176-1G>A N/A Heterozygous Splicing defect rs141317482 0.004691 0.0051
F13.1 STXBP5L c.G1135A p.V379M Heterozygous Missense rs61996323 0.006289 0.006
F16.1 VPS41 c.2528G>A p.R843H Heterozygous Missense rs1059508 0.020145 0.0069
F17.1 SYTL3 c.259G>T p.V87L Heterozygous Missense Novel
F17.1 c.205G>T p.V69L Heterozygous Missense N/A No data 0.0014
F17.1 VPS4B c.1329A>C p.E443D Heterozygous Missense Novel
F13.1 HOOK3 c.1945-3dup N/A Homozygous Splicing defect Novel
F18.1 VPS16 c.515-10C>T N/A Heterozygous Splicing defect rs45564738 0.006843 0.0032
F18.1 SCFD1 c.1021A>G p.T341A Heterozygous Missense rs1754285 0.01464 0.0073
F13.1 STXBP1 c.38-3T>C N/A Heterozygous Splicing defect rs138763389 0.013994 0.0074
F15.1 c.325+8C>T N/A Heterozygous Splicing defect rs117372398 0.003383 0.0014
F17.1 STXBP2 c.828-4C>T N/A Heterozygous Splicing defect rs151257815 0.013686 0.0078
MAF, minor allele frequency; EVS, exome variant server.
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taxin genes, further supporting a role for the SNARE-
complex in platelet-dense granule biogenesis and secre-
tion. Although homozygous defects were found to be
more common among the patients with the dense granule
secretion disorders, only one of the eight genes that were
shown to bear candidate homozygous defects remained
after functional annotation analysis of the data. This was
a homozygous splice site defect in HOOK 3, which
encodes a microtubule tethering protein that is believed
to have a role in vesicle trafficking [28], and the patient
with this defect (F13.1) was also heterozygous for a splic-
ing defect in STXBP1 and a missense mutation in
STXBP5L. Further work is required to determine the rel-
ative contribution, if any, of these defects to the bleeding
tendency in this patient.
Importantly, functional annotation analysis has identi-
fied distinctly different sets of genes associated with Gi
signaling and secretion abnormalities and has allowed
segregation of the two groups of patients. This finding
highlights the value of platelet phenotyping not only in
allowing assignment of PFDs into diagnostic subgroups
but also in directing downstream studies leading to the
identification of the underlying genetic defects. Further
studies will be required to determine which, if any, of the
candidate defects identified in this study explain the dif-
ferent bleeding disorders, although the functional annota-
tion analysis has highlighted plausible candidates.
However, it remains likely that the bleeding diatheses
experienced by the index cases and affected family mem-
bers are explained by the specific combination of candi-
date platelet gene defects inherited and that the
expression of the bleeding tendency will, in turn, be
affected by an interaction with other nongenetic factors,
such as surgery, to determine the overall risk of bleeding.
While exome sequencing and targeted platelet gene
analysis have allowed us to identify and prioritize candi-
date gene defects that could underlie or contribute to the
platelet function defects observed in the index cases stud-
ied, our approach does have limitations. It is possible that
other causative gene defects have been overlooked in our
panel of platelet genes as a result of the strategies used to
prioritize the candidate gene defects for further follow-up
studies. Causative gene defects in the non-coding regions
of the targeted platelet genes, which are not included in
the exome, or indeed in other genes that are not in our
panel of platelet genes, would also be overlooked by our
approach. The potential for other genetic mechanisms,
such as copy number variation, large indels, or structural
genomic variants, to contribute to the underlying defects
also cannot be discounted. Although further studies are
required to confirm the pathogenicity of the candidate
defects identified in this study, our approach has high-
lighted several plausible candidate genes for targeted
analysis in patients with abnormalities of platelet secre-
tion and Gi signaling abnormalities.
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